Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 772-778

  Leblond, V ^a   Dhedin, N ^a   Bruneel, M F M ^a   Choquet, S ^a   Hermine, O ^a   Porcher, R ^a   Qouc, S N ^a   Davi, F ^a   Charlotte, F ^a   Dorent, R ^a   Borrou, B ^a   Vernant, J P ^a   Raphael, M ^a   Levy, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL RATE; TUMOR LOCALIZATION; VIRUS DETECTION;

EID: 0035253727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.772     Document Type: Article

References (33)

1. Cancers complicating organ transplantation
2. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity?
3. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients: Collaborative Transplant Study
4. Lymphoproliferative disorders after organ transplantation: A report of 24 cases in a single center
5. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients
6. Postransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of Cyclosporine-based immunosuppression
7. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
8. Epstein-Barr virus, immunodeficiency, and B-cell lymphoproliferation
9. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
10. The international non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma
11. Prognosic factors in aggressive non-hodgkin lymphoma: Who has "high-risk" disease?
12. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
13. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody
14. Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice
15. Humanized anti-CD20 monoclonal antobody (Rituximab) in B posttransplant lymphoproliferative disorders: A retrospective analysis on 32 patients
16. Posttransplant lymphoproliferative disorders: Summary of Society for Hemathopathology Workshop
17. Use of avidin biotin peroxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabelled (PAP) procedures
18. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphate anti alkaline phosphatase (APAAP complex)
19. Rapid in situ hybridization for the diagnosis of latent Epstein-Barr virus infection
20. Non parametric estimation from incomplete observations
21. Regression models and life tables
22. Proportional hazards tests and diagnostics based on weighted residual
23. Epstein-Barr virus latent membrane protein-1 oncogene deletions correlations with malignancy in Epstein-Barr associated lymphoproliferative disorders and malignant lymphomas
24. Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in post transplantation lymphoproliferative disorders
25. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
26. Central nervous system in organ allograft recipients
27. A unified approach to posttransplant lymphoproliferative disorder (PTLD): Improved outcome and analysis of prognostic factor
28. Characterization of posttransplant lymphomas that express T-cell-associated markers: Immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice
29. Posttransplant T-cell lymphoproliferative disorders: An aggressive, late complication of solid-organ transplantation
30. Clinical characteristics of posttransplant lymphoproliferative disorders
31. Aggressive treatment for postcardiac transplant lymphoproliferation
32. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy
33. Posttransplant lymphoproliferative disorders (PTLD): Long-term outcome and prognostic factors